AAN.com
Quick search in Citations
AnywhereCitation
Advanced Search
Trending Terms:
Article
February 27, 2013

Brain β-amyloid load approaches a plateau

Clifford R. Jack, Jr, MD, Heather J. Wiste, Timothy G. Lesnick, Stephen D. Weigand, David S. Knopman, MD, Prashanthi Vemuri, PhD, Vernon S. Pankratz, PhD, … Show All … , Matthew L. Senjem, Jeffrey L. Gunter, PhD, Michelle M. Mielke, PhD, Val J. Lowe, MD, Bradley F. Boeve, MD, and Ronald C. Petersen, MD, PhDAuthors Info & Affiliations
March 5, 2013 issue
80 (10) 890-896
https://doi.org/10.1212/WNL.0b013e3182840bbe
Letters to the Editor
Track CitationsAdd to favorites
Get Access

Abstract

Objective:

To model the temporal trajectory of β-amyloid accumulation using serial amyloid PET imaging.

Methods:

Participants, aged 70–92 years, were enrolled in either the Mayo Clinic Study of Aging (n = 246) or the Mayo Alzheimer's Disease Research Center (n = 14). All underwent 2 or more serial amyloid PET examinations. There were 205 participants classified as cognitively normal and 55 as cognitively impaired (47 mild cognitive impairment and 8 Alzheimer dementia). We measured baseline amyloid PET-relative standardized uptake values (SUVR) and, for each participant, estimated a slope representing their annual amyloid accumulation rate. We then fit regression models to predict the rate of amyloid accumulation given baseline amyloid SUVR, and evaluated age, sex, clinical group, and APOE as covariates. Finally, we integrated the amyloid accumulation rate vs baseline amyloid PET SUVR association to an amyloid PET SUVR vs time association.

Results:

Rates of amyloid accumulation were low at low baseline SUVR. Rates increased to a maximum at baseline SUVR around 2.0, above which rates declined—reaching zero at baseline SUVR above 2.7. The rate of amyloid accumulation as a function of baseline SUVR had an inverted U shape. Integration produced a sigmoid curve relating amyloid PET SUVR to time. The average estimated time required to travel from an SUVR of 1.5–2.5 is approximately 15 years.

Conclusion:

This roughly 15-year interval where the slope of the amyloid SUVR vs time curve is greatest and roughly linear represents a large therapeutic window for secondary preventive interventions.

Get full access to this article

View all available purchase options and get full access to this article.

Get Access

Supplementary Material

File (jack_890.pdf)
File (wnl204757.pdf)

REFERENCES

1.
Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009;65:176–183.
Crossref
PubMed
Google Scholar
2.
Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65:403–413.
Crossref
PubMed
Google Scholar
3.
Jagust WJ, Zheng L, Harvey DJ, et al. Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol 2008;63:72–80.
Crossref
PubMed
Google Scholar
4.
Vemuri P, Whitwell JL, Kantarci K, et al. Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage 2008;42:559–567.
Crossref
PubMed
Google Scholar
5.
Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306–319.
Crossref
PubMed
Google Scholar
6.
Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31:1275–1283.
Crossref
PubMed
Google Scholar
7.
Sojkova J, Zhou Y, An Y, et al. Longitudinal patterns of beta-amyloid deposition in nondemented older adults. Arch Neurol 2011;68:644–649.
Crossref
PubMed
Google Scholar
8.
Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119–128.
Crossref
PubMed
Google Scholar
9.
Ingelsson M, Fukumoto H, Newell KL, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004;62:925–931.
Crossref
PubMed
Google Scholar
10.
Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006;129:2856–2866.
Crossref
PubMed
Google Scholar
11.
Jack CR, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355–1365.
Crossref
PubMed
Google Scholar
12.
Jack CR, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008;131:665–680.
Crossref
PubMed
Google Scholar
13.
Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005;46:1959–1972.
PubMed
Google Scholar
14.
Jack CR, Vemuri P, Wiste HJ, et al. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 2011;68:1526–1535.
Crossref
PubMed
Google Scholar
15.
Caroli A, Frisoni GB. The dynamics of Alzheimer's disease biomarkers in the Alzheimer's disease Neuroimaging Initiative cohort. Neurobiol Aging 2010;31:1263–1274.
Crossref
PubMed
Google Scholar
16.
Lo RY, Hubbard AE, Shaw LM, et al. Longitudinal change of biomarkers in cognitive decline. Arch Neurol 2011;68:1257–1266.
Crossref
PubMed
Google Scholar
17.
Jack CR, Vemuri P, Wiste HJ, et al. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol 2012;69:856–867.
Crossref
PubMed
Google Scholar
18.
Rentz DM, Locascio JJ, Becker JA, et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 2010;67:353–364.
Crossref
PubMed
Google Scholar
19.
Vemuri P, Weigand SD, Przybelski SA, et al. Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain 2011;134:1479–1492.
Crossref
PubMed
Google Scholar
20.
Reed BR, Mungas D, Farias ST, et al. Measuring cognitive reserve based on the decomposition of episodic memory variance. Brain 2010;133:2196–2209.
Crossref
PubMed
Google Scholar
21.
Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131:1630–1645.
Crossref
PubMed
Google Scholar
22.
Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011;305:275–283.
Crossref
PubMed
Google Scholar
23.
Fleisher AS, Chen K, Liu X, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 2011;68:1404–1411.
Crossref
PubMed
Google Scholar
24.
Sojkova J, Driscoll I, Iacono D, et al. In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol 2011;68:232–240.
Crossref
PubMed
Google Scholar
25.
Mormino EC, Brandel MG, Madison CM, et al. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage 2012;59:1152–1160.
Crossref
PubMed
Google Scholar
26.
Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67:122–131.
Crossref
PubMed
Google Scholar
27.
Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011;69:181–192.
Crossref
PubMed
Google Scholar
28.
Vlassenko AG, Mintun MA, Xiong C, et al. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol 2011;70:857–861.
Crossref
PubMed
Google Scholar
29.
Rodrigue KM, Kennedy KM, Devous MD, et al. beta-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology 2012;78:387–395.
Crossref
PubMed
Google Scholar
30.
Becker JA, Hedden T, Carmasin J, et al. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol 2011;69:1032–1042.
Crossref
PubMed
Google Scholar
31.
Jack CR, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010;133:3336–3348.
Crossref
PubMed
Google Scholar
32.
Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2009;106:6820–6825.
Crossref
PubMed
Google Scholar
33.
Kantarci K, Lowe V, Przybelski SA, et al. APOE modifies the association between Abeta load and cognition in cognitively normal older adults. Neurology 2012;78:232–240.
Crossref
PubMed
Google Scholar
34.
Vemuri P, Wiste HJ, Weigand SD, et al. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol 2010;67:308–316.
Crossref
PubMed
Google Scholar
35.
Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 2009;461:916–922.
Crossref
PubMed
Google Scholar
36.
Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009;132:1310–1323.
Crossref
PubMed
Google Scholar
37.
Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol 2011;68:1062–1064.
Crossref
PubMed
Google Scholar
38.
Villemagne VL, Ong K, Mulligan RS, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011;52:1210–1217.
Crossref
PubMed
Google Scholar
39.
Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 2011;17:1060–1065.
Crossref
PubMed
Google Scholar
40.
Sperling RA, Jack CR, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med 2011;3:111cm33.
Crossref
PubMed
Google Scholar

Information & Authors

Information

Published In

Neurology®
Volume 80 • Number 10 • March 5, 2013
Pages: 890-896
PubMed: 23446680

Copyright

© 2013 American Academy of Neurology.

Publication History

Received: June 1, 2012
Accepted: September 25, 2012
Published online: February 27, 2013
Published in print: March 5, 2013

Permissions

Request permissions for this article.

Disclosure

C.R. Jack serves as a consultant for Janssen, Bristol-Meyer-Squibb, General Electric, and Johnson and Johnson, and is involved in clinical trials sponsored by Allon and Baxter, Inc. He receives research funding from the NIH (R01-AG011378, RO1-AG037551, U01-HL096917, U01-AG032438, U01-AG024904) and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation. H. Wiste, T. Lesnick, and S. Weigand report no disclosures. D. Knopman serves as Deputy Editor for Neurology®, serves on a Data Safety Monitoring Board for Lilly Pharmaceuticals, is an investigator in clinical trials sponsored by Janssen Pharmaceuticals, and receives research support from the NIH. P. Vemuri reports no disclosures. V.S. Pankratz is funded by the NIH (R01AG040042, U01AG06786, Mayo Clinic Alzheimer's Disease Research Center/Core C P50AG16574/Core C, and R01AG32990). M. Senjem, J. Gunter, and M. Mielke report no disclosures. V. Lowe serves on scientific advisory boards for Bayer Schering Pharma and GE Healthcare and receives research support from GE Healthcare, Siemens Molecular Imaging, the NIH (NIA, NCI), the MN Partnership for Biotechnology and Medical Genomics, and the Leukemia & Lymphoma Society. B. Boeve has served as a consultant to GE Healthcare; receives publishing royalties for The Behavioral Neurology of Dementia (Cambridge University Press, 2009); and receives research support from Cephalon, Inc., Allon Therapeutics, Inc., the NIH/NIA, the Alzheimer's Association, and the Mangurian Foundation. R. Petersen reports receiving consulting fees from Elan Pharmaceuticals and GE Healthcare, receiving royalties from Oxford University Press, and serving as chair of data monitoring committees for Pfizer and Janssen Alzheimer Immunotherapy; and receives research support from the NIH/NIA. Go to Neurology.org for full disclosures.

Study Funding

Funding sources include the NIH, National Institute on Aging R01 AG11378, P50 AG16574, and U01 AG06786. The General Electric Corporation also provided funding for some imaging studies used in this analysis. Also supported by US NIH Construction Grant (NIH C06 RR018898), The Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation, USA, and the Robert H. and Clarice Smith Alzheimer's Disease Research Program of the Mayo Foundation.

Authors

Affiliations & Disclosures

Clifford R. Jack, Jr, MD
From the Departments of Radiology (C.R.J., P.V., M.L.S., J.L.G.), Health Sciences Research (H.J.W., T.G.L., S.D.W., V.S.P.), Neurology (D.S.K., B.F.B., R.C.P.), Epidemiology (M.M.M.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN.
Disclosure
Scientific Advisory Boards:
1.
scientific advisory panels: (1) Elan, (2) Lilly, (3) GE, (4) Eisai, (5) Janssen, (6) Johnson and Johnson, (7) Bristol Meyer Squibb, (8) Siemens
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
Investigator in clinical trials sponsored by Baxter, Allon, and the National Institute on Aging
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Allon and Baxter, perform MRI related services for clinical trial
Research Support, Government Entities:
1.
RO1 AG11378 PI; U01 AG024904-01 co-I; RO1 AG37551 co-I; 1U01HL096917 co-I; U01 AG032438 co-I
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
Johnson and Johnson, 2010
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Heather J. Wiste
From the Departments of Radiology (C.R.J., P.V., M.L.S., J.L.G.), Health Sciences Research (H.J.W., T.G.L., S.D.W., V.S.P.), Neurology (D.S.K., B.F.B., R.C.P.), Epidemiology (M.M.M.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Timothy G. Lesnick
From the Departments of Radiology (C.R.J., P.V., M.L.S., J.L.G.), Health Sciences Research (H.J.W., T.G.L., S.D.W., V.S.P.), Neurology (D.S.K., B.F.B., R.C.P.), Epidemiology (M.M.M.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Stephen D. Weigand
From the Departments of Radiology (C.R.J., P.V., M.L.S., J.L.G.), Health Sciences Research (H.J.W., T.G.L., S.D.W., V.S.P.), Neurology (D.S.K., B.F.B., R.C.P.), Epidemiology (M.M.M.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
David S. Knopman, MD
From the Departments of Radiology (C.R.J., P.V., M.L.S., J.L.G.), Health Sciences Research (H.J.W., T.G.L., S.D.W., V.S.P.), Neurology (D.S.K., B.F.B., R.C.P.), Epidemiology (M.M.M.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN.
Disclosure
Scientific Advisory Boards:
1.
Lilly Pharmaceuticals, Data Safety Monitoring Board, ended 8/22/12; TauRx consultant 2012; Consultant, McGill University Alzheimer Program 9/19/12
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Lecture, University of Toronto, March 2012
Editorial Boards:
1.
Neurology, Deputy Editor
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) Janssen Alzheimer Immunotherapy program 3/29/11: honorarium paid to my institution; (2) Merck Alzheimer program 11/5/11 paid to my institution.
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) Janssen for Alzheimer clinical trial, (2) Forest Laboratories for clinical trial in FTLD with memantine, (3) Baxter Laboratories for Alzheimer Clinical trial
Research Support, Government Entities:
1.
NIH: R01-AG11378 ongoing, P50-AG 16574 (Mayo Alzheimer's Disease Research Center) ongoing, U01 AG 06786 (Mayo Alzheimer Disease Patient Registry) ongoing. NIH R01 AG32306 FTD Neuro-imaging;Initiative. 1U01HL096917-01 ARIC Dementia Study.AG 037551 Chronic Kidney Disease and Cognitive functioning.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Prashanthi Vemuri, PhD
From the Departments of Radiology (C.R.J., P.V., M.L.S., J.L.G.), Health Sciences Research (H.J.W., T.G.L., S.D.W., V.S.P.), Neurology (D.S.K., B.F.B., R.C.P.), Epidemiology (M.M.M.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Vernon S. Pankratz, PhD
From the Departments of Radiology (C.R.J., P.V., M.L.S., J.L.G.), Health Sciences Research (H.J.W., T.G.L., S.D.W., V.S.P.), Neurology (D.S.K., B.F.B., R.C.P.), Epidemiology (M.M.M.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) NIA, P50 AG16574, Data Core Director, 2004-present(2) NIA, U01 AG06786, Co-Investigator, 2005-present(3) NIA, R01 AG32990, Co-Investigator, 2009-present
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Matthew L. Senjem
From the Departments of Radiology (C.R.J., P.V., M.L.S., J.L.G.), Health Sciences Research (H.J.W., T.G.L., S.D.W., V.S.P.), Neurology (D.S.K., B.F.B., R.C.P.), Epidemiology (M.M.M.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Jeffrey L. Gunter, PhD
From the Departments of Radiology (C.R.J., P.V., M.L.S., J.L.G.), Health Sciences Research (H.J.W., T.G.L., S.D.W., V.S.P.), Neurology (D.S.K., B.F.B., R.C.P.), Epidemiology (M.M.M.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Employment at Mayo Clinic
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Michelle M. Mielke, PhD
From the Departments of Radiology (C.R.J., P.V., M.L.S., J.L.G.), Health Sciences Research (H.J.W., T.G.L., S.D.W., V.S.P.), Neurology (D.S.K., B.F.B., R.C.P.), Epidemiology (M.M.M.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Dr. Mielke was funded by the following NIH grants:U01 AG037526, role: PI, Date: 08/15/2010-06/30/2015;R21 NS06027-01, role: PI, Date: 07/15/07-06/30/09;R21 AG028754, role: PI, Date: 09/01/07-08/31/09'R01 AG21136, role: Investigator, Date: 9/01/02-8/31/08
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Dr. Mielke also received research support from the Georgeand Cynthia Mitchell Foundation. Role: co-PI, Date: 07/01/2007-06/30/2010 and Walter S. and Lucienne B. Driskill Foundation which started in May 2012.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Val J. Lowe, MD
From the Departments of Radiology (C.R.J., P.V., M.L.S., J.L.G.), Health Sciences Research (H.J.W., T.G.L., S.D.W., V.S.P.), Neurology (D.S.K., B.F.B., R.C.P.), Epidemiology (M.M.M.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN.
Disclosure
Scientific Advisory Boards:
1.
(1) Bayer Pharmaceuticals
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) GE Health Care(2) Siemens Molecular Imaging(3) AVID Radiopharmaceuticals
Research Support, Government Entities:
1.
(1) NIA R01 DC010367-01, CoI, 12/01/09-11/30/14(2) NIA P50 AG016574-12, Co-PI Project #1, 05/01/09-04/30/14(3) NIA R01 AG011378-16, CoI, 06/01/08-05/31/13(4) NCI R01 CA136526-02, CoI, 01/01/09-11/30/14(5) P30 CA015083-35, Program Director, 07/01/09-06/30/1(6) P50 CA102701-07, CoI, 09/01/08-08/31/13(7) R01 CA125614-04, CoI,09/26/06-07/31/11(8)R21 CA123909-02, CoI, 07/01/07-08/01/12
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1)MN Partnership for Biotechnology and Medical Genomics, PI, 01/01/09-12/31/12
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Bradley F. Boeve, MD
From the Departments of Radiology (C.R.J., P.V., M.L.S., J.L.G.), Health Sciences Research (H.J.W., T.G.L., S.D.W., V.S.P.), Neurology (D.S.K., B.F.B., R.C.P.), Epidemiology (M.M.M.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
Behavioral Neurology Of Dementia, Cambridge Univeristy Press, 2009
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Grant support as an investigator in clinical trials funded by (1) Cephalon, Inc., 2009-present, (2) Allon Therapeutics, Inc., 2010-present; and (3) GE Healthcare, 2012-present.
Research Support, Government Entities:
1.
(1) National Institute on Aging [P50 AG016574 (Co-Investigator, 2009-present), U01 AG006786 (Co-Investigator, 2009-present), RO1 AG032306 (Co-Investigator, 2010-present)(2) Center for Inherited Disease Research [U24 AG026395 (Co-Investigator, 2009-present)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Mangurian Foundation, 2011-present
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Ronald C. Petersen, MD, PhD
From the Departments of Radiology (C.R.J., P.V., M.L.S., J.L.G.), Health Sciences Research (H.J.W., T.G.L., S.D.W., V.S.P.), Neurology (D.S.K., B.F.B., R.C.P.), Epidemiology (M.M.M.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN.
Disclosure
Scientific Advisory Boards:
1.
(1) Pfizer, Inc., Chair, Data Monitoring Committee ; (2) Janssen Alzheimer Immunotherapy, Chair, Data Monitoring Committee
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
Mild Cognitive Impairment,Oxford University Press, 2003
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) Elan Pharmaceuticals, (2) GE Healthcare
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
Novartis CME lecture
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
National Institute on Aging:U01-AG006786 (PI) (1986-present)P50-AG016574 (PI) (1990-present)R01-AG011378 (Co-I)U01-AG024904 (Co-I)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author

Notes

Correspondence to Dr. Jack: [email protected]
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Author Contributions

Clifford R. Jack: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, contribution of vital reagents/tools/patients, acquisition of data, statistical analysis, study supervision, obtaining funding. Heather Wiste: drafting/revising the manuscript, analysis or interpretation of data, statistical analysis. Timothy G. Lesnick: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, statistical analysis. Stephen D. Weigand: drafting/revising the manuscript, analysis or interpretation of data, statistical analysis. David S. Knopman: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, acquisition of data. Prashanthi Vemuri: drafting/revising the manuscript, analysis or interpretation of data. Vernon Shane Pankratz: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, statistical analysis. Matthew L. Senjem: drafting/revising the manuscript, analysis or interpretation of data, contribution of vital reagents/tools/patients, acquisition of data, statistical analysis. Jeffrey L. Gunter: drafting/revising the manuscript, analysis or interpretation of data, statistical analysis. Michelle M. Mielke: drafting/revising the manuscript, analysis or interpretation of data. Val J. Lowe: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, contribution of vital reagents/tools/patients, acquisition of data, study supervision, obtaining funding. Bradley F. Boeve: analysis or interpretation of data, acquisition of data. Ronald C. Petersen: drafting/revising the manuscript, obtaining funding.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
    • Seyed Hani Hojjati,
    • Gloria C. Chiang,
    • Tracy A. Butler,
    • Mony de Leon,
    • Ajay Gupta,
    • Yi Li,
    • Mert R. Sabuncu,
    • Farnia Feiz,
    • Siddharth Nayak,
    • Jacob Shteingart,
    • Sindy Ozoria,
    • Saman Gholipour Picha,
    • Yaakov Stern,
    • José A. Luchsinger,
    • Davangere P. Devanand,
    • Qolamreza R. Razlighi,
    Remote Associations Between Tau and Cortical Amyloid-β Are Stage-Dependent, Journal of Alzheimer's Disease, 98, 4, (1467-1482), (2024).https://doi.org/10.3233/JAD-231362
    Crossref
    • Brenda L. Plassman,
    • Cassie B. Ford,
    • Valerie A. Smith,
    • Nicole DePasquale,
    • James R. Burke,
    • Laura Korthauer,
    • Brian R. Ott,
    • Emmanuelle Belanger,
    • Megan E. Shepherd-Banigan,
    • Elyse Couch,
    • Eric Jutkowitz,
    • Emily C. O’Brien,
    • Corinna Sorenson,
    • Terrie T. Wetle,
    • Courtney H. Van Houtven,
    Elevated Amyloid-β PET Scan and Cognitive and Functional Decline in Mild Cognitive Impairment and Dementia of Uncertain Etiology, Journal of Alzheimer's Disease, 97, 3, (1161-1171), (2024).https://doi.org/10.3233/JAD-230950
    Crossref
    • William J. Jagust,
    • Venkata S. Mattay,
    • Daniel M. Krainak,
    • Sue-Jane Wang,
    • Lora D. Weidner,
    • A. Alex Hofling,
    • Hayoung Koo,
    • Pamela Hsieh,
    • Phillip H. Kuo,
    • Gill Farrar,
    • Libero Marzella,
    Quantitative Brain Amyloid PET, Journal of Nuclear Medicine, 65, 5, (670-678), (2024).https://doi.org/10.2967/jnumed.123.265766
    Crossref
    • Cindyawati Cindyawati,
    • Faozan Ahmad,
    • Hendradi Hardhienata,
    • Agus Kartono,
    Development of Aβ and anti-Aβ dynamics models for Alzheimer’s disease, Computational and Mathematical Biophysics, 12, 1, (2024).https://doi.org/10.1515/cmb-2024-0008
    Crossref
    • Oscar L. Lopez,
    • Victor L. Villemagne,
    • Yue-Fang Chang,
    • Ann D. Cohen,
    • William E. Klunk,
    • Chester A. Mathis,
    • Tharick Pascoal,
    • Milos D. Ikonomovic,
    • Christopher Rowe,
    • Vincent Dore,
    • Beth E. Snitz,
    • Brian J. Lopresti,
    • M. Ilyas Kamboh,
    • Howard J. Aizenstein,
    • Lewis H. Kuller,
    Association Between β-Amyloid Accumulation and Incident Dementia in Individuals 80 Years or Older Without Dementia, Neurology, 102, 2, (2024)./doi/10.1212/WNL.0000000000207920
    Abstract
    • Nathaniel B. Gunter,
    • Robel K. Gebre,
    • Jonathan Graff-Radford,
    • Michael G. Heckman,
    • Clifford R. Jack,
    • Val J. Lowe,
    • David S. Knopman,
    • Ronald C. Petersen,
    • Owen A. Ross,
    • Prashanthi Vemuri,
    • Vijay K. Ramanan,
    Machine Learning Models of Polygenic Risk for Enhanced Prediction of Alzheimer Disease Endophenotypes, Neurology Genetics, 10, 1, (2024)./doi/10.1212/NXG.0000000000200120
    Abstract
    • Junpeng Li,
    • Qi Huang,
    • Na Qi,
    • Kun He,
    • Songye Li,
    • Lin Huang,
    • Fengfeng Pan,
    • Shuhua Ren,
    • Fengchun Hua,
    • Yiyun Huang,
    • Yihui Guan,
    • Qihao Guo,
    • Jun Zhao,
    • Fang Xie,
    The associations between synaptic density and “A/T/N” biomarkers in Alzheimer’s disease: An 18 F-SynVesT-1 PET/MR study , Journal of Cerebral Blood Flow & Metabolism, 44, 7, (1199-1207), (2024).https://doi.org/10.1177/0271678X241230733
    Crossref
    • Daniel Naawenkangua Abukuri,
    Novel Biomarkers for Alzheimer’s Disease: Plasma Neurofilament Light and Cerebrospinal Fluid, International Journal of Alzheimer's Disease, 2024, (1-15), (2024).https://doi.org/10.1155/2024/6668159
    Crossref
    • Arina A. Tagmazian,
    • Claudia Schwarz,
    • Catharina Lange,
    • Esa Pitkänen,
    • Eero Vuoksimaa,
    ArcheD, a residual neural network for prediction of cerebrospinal fluid amyloid‐beta from amyloid PET images, European Journal of Neuroscience, 59, 11, (3030-3044), (2024).https://doi.org/10.1111/ejn.16332
    Crossref
    • G. Malu,
    • Nayana Uday,
    • Elizabeth Sherly,
    • Ajith Abraham,
    • Narendra Kuber Bodhey,
    CirMNet: A Shape-Based Hybrid Feature Extraction Technique Using CNN and CMSMD for Alzheimer’s MRI Classification, IEEE Access, 12, (80491-80504), (2024).https://doi.org/10.1109/ACCESS.2024.3408311
    Crossref
  11. See more

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share

View full text|Download PDF